Search Back New search Go to resultsDiseaseMain groupSupportive Therapy, ToxicityProtocol groupComplicationsDiseaseCytokine Release SyndromeSubgroupICD10MeSHSequenceChemotherapyChemo-substanceChemo-substanceChemo-substanceChemo-substanceNo. Substances RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionTocilizumabSupportive substanceBalanced Crystalloid SolutionTocilizumabSupportive substanceBalanced Crystalloid SolutionTocilizumabSupportive substanceBalanced Crystalloid SolutionTocilizumabNo. Substances2Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationTherapy phaseTherapy intentionRisksEmetogenicity only studiesPublicationAuthorLe RQDiseaseCAR-T-Zell-induziertes Zytokin-Freisetzungs-SyndromOriginCenter for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USAProtocols in Revision 1 protocol foundProtocols under revision.Tocilizumab 8, Cytokine release Syndrome (PID1833 V1.0)
